@article{oai:tsukuba.repo.nii.ac.jp:00055897,
 author = {佐藤, 浩昭 and SATOH, Hiroaki and 檜澤, 伸之 and HIZAWA, Nobuyuki and Watanabe, Hiroko and Okauchi, Shinichiro and Miyazaki, Kunihiko},
 issue = {11},
 journal = {Polskie archiwum medycyny wewnȩtrznej, Polish archives of internal medicine},
 month = {Nov},
 note = {An epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) was shown to increase the number of long-term survivors among patients with non–small-cell lung cancer (NSCLC) associated with the mutation of the EGFR gene.1 However, considering the limitations of current medical technology, it is difficult to expect a cure for this disease.2 In most patients, the regrowth of the primary tumor and metastases are observed. Unfortunately, depending on the site of recurrence, treatment of numerous patients with severe metastasis is difficult. Recurrent leptomeningeal metastases are particularly challenging. Meningeal metastasis is defined as a condition in which tumor cells have spread and invaded the surface of the brain and subarachnoid space, and then the ventricles and cisterns via the cerebrospinal fluid.3 The metastasis causes various neurologic symptoms and is often difficult to diagnose.3 As there is no established treatment for cancer recurrence after an effective therapy with an EGFR-TKI, patients may experience a reduced quality of life, become bedridden, and eventually die.3 Therefore, it is important to identify factors that are related to cancer recurrence. In this study, in addition to standard clinicopathological factors, we examined factors related to recurrence in the meninges, which is associated with metastases to other organs.},
 pages = {836--838},
 title = {Factors associated with recurrent leptomeningeal metastases in patients with EGFR-mutated non–small-cell lung cancer},
 volume = {129},
 year = {2019},
 yomi = {サトウ, ヒロアキ and ヒザワ, ノブユキ}
}